The State of Alzheimer's Funding and Research: A Conversation with Robert Egge (April 30th)
www.thehealthcarepolicypodcast.com
Listen now (26 mins) | Listen Now Alzheimer's Disease accounts for approximately 70% of all dementia diagnoses. The disease affects over five million Americans or upwards of 35 million worldwide. Disease burden is currently estimated to grow to 16 million patients in the US by 2050 with projected costs estimated at over $1 trillion. Patients diagnosed with Alzheimer's survive three to nine years. The disease kills 500,000 deaths annually, making it the 6th leading cause of death. The risk of the disease is believed to be largely genetic. There are currently no treatments or medications to stop, reverse or modify its progression - the only major disease with this distinction.
The State of Alzheimer's Funding and Research: A Conversation with Robert Egge (April 30th)
The State of Alzheimer's Funding and…
The State of Alzheimer's Funding and Research: A Conversation with Robert Egge (April 30th)
Listen now (26 mins) | Listen Now Alzheimer's Disease accounts for approximately 70% of all dementia diagnoses. The disease affects over five million Americans or upwards of 35 million worldwide. Disease burden is currently estimated to grow to 16 million patients in the US by 2050 with projected costs estimated at over $1 trillion. Patients diagnosed with Alzheimer's survive three to nine years. The disease kills 500,000 deaths annually, making it the 6th leading cause of death. The risk of the disease is believed to be largely genetic. There are currently no treatments or medications to stop, reverse or modify its progression - the only major disease with this distinction.